Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Feels Ill Effects Of Mild Cold Season, Excess OTC Capacity

This article was originally published in The Tan Sheet

Executive Summary

The private labeler lowered its full-year revenue guidance, noting weak cough/cold/flu OTC sales. Perrigo built up excess capacity to take advantage of recalled Johnson & Johnson OTCs, and now is shifting some capacity in response to a Novartis plant shutdown.

Advertisement

Related Content

Bayer Migraine Formula Seeks Market Share Before Excedrin Returns
Bayer Migraine Formula Seeks Market Share Before Excedrin Returns
OTC Answers Website Plays Up Brands In Self-Selection Engine
OTC Answers Website Plays Up Brands In Self-Selection Engine
Perrigo Squares Off With Dr. Reddy’s In Lansoprazole Launch
McNeil Remediation Stretches Out, Dragging On J&J Consumer Sales
Perrigo Relies On New Products For Fiscal Second-Half Boost
Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions
LIPIL for Moms

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel